Bispecific Antibodies: The Case for Non-BCMA Targets

Join Dr Chari as he reviews the rationale and clinical evidence of novel non-BCMA-targeted bispecific antibodies for patients with R/R multiple myeloma. Credit available for this activity expires: 6/10/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/952772?src=mkm_podcast_addon_952772